A Phase 1/2 Study of CFT8919 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 10 Jul 2023
Price :
$35 *
At a glance
- Drugs CFT 8919 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors C4 Therapeutics
- 05 Jul 2023 According to a C4 Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CFT8919.
- 09 Jan 2023 According to a C4 Therapeutics media release, the company anticipates to submit an IND application in the first half of 2023.
- 05 May 2022 According to a C4 Therapeutics media release, company anticipate to complete IND-enabling activities for CFT8919 by year-end 2022.